CN112602778A - Laxative sleep-aiding milk powder containing lactobacillus paracasei N1115 and preparation method thereof - Google Patents
Laxative sleep-aiding milk powder containing lactobacillus paracasei N1115 and preparation method thereof Download PDFInfo
- Publication number
- CN112602778A CN112602778A CN202011562978.9A CN202011562978A CN112602778A CN 112602778 A CN112602778 A CN 112602778A CN 202011562978 A CN202011562978 A CN 202011562978A CN 112602778 A CN112602778 A CN 112602778A
- Authority
- CN
- China
- Prior art keywords
- sleep
- lactobacillus paracasei
- milk powder
- aiding
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000843 powder Substances 0.000 title claims abstract description 84
- 235000013336 milk Nutrition 0.000 title claims abstract description 58
- 239000008267 milk Substances 0.000 title claims abstract description 58
- 210000004080 milk Anatomy 0.000 title claims abstract description 58
- 241000186315 Lactobacillus paracasei N1115 Species 0.000 title claims abstract description 55
- 230000002475 laxative effect Effects 0.000 title claims abstract description 35
- 239000008141 laxative Substances 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 22
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 11
- 230000001580 bacterial effect Effects 0.000 claims description 14
- 239000002994 raw material Substances 0.000 claims description 12
- 230000002040 relaxant effect Effects 0.000 claims description 9
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 8
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 8
- 241000186000 Bifidobacterium Species 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 4
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 3
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 3
- 229920001100 Polydextrose Polymers 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims description 2
- 235000021552 granulated sugar Nutrition 0.000 claims description 2
- 235000013856 polydextrose Nutrition 0.000 claims description 2
- 229940035035 polydextrose Drugs 0.000 claims description 2
- 239000001259 polydextrose Substances 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 235000008476 powdered milk Nutrition 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 15
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 11
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 230000007413 intestinal health Effects 0.000 abstract description 4
- 230000001050 lubricating effect Effects 0.000 abstract description 3
- 230000009044 synergistic interaction Effects 0.000 abstract description 3
- 235000016709 nutrition Nutrition 0.000 abstract description 2
- 230000035764 nutrition Effects 0.000 abstract description 2
- 230000001502 supplementing effect Effects 0.000 abstract description 2
- 241000186605 Lactobacillus paracasei Species 0.000 abstract 1
- 230000035622 drinking Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 33
- 238000002474 experimental method Methods 0.000 description 29
- 239000000976 ink Substances 0.000 description 19
- 239000013641 positive control Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 210000003608 fece Anatomy 0.000 description 12
- 230000004622 sleep time Effects 0.000 description 12
- 230000004620 sleep latency Effects 0.000 description 11
- 210000000813 small intestine Anatomy 0.000 description 11
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 8
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 8
- 230000013872 defecation Effects 0.000 description 7
- 229960002275 pentobarbital sodium Drugs 0.000 description 7
- 238000003304 gavage Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 229960000796 barbital sodium Drugs 0.000 description 4
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 4
- 229940125717 barbiturate Drugs 0.000 description 4
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 4
- 206010016100 Faeces discoloured Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940099352 cholate Drugs 0.000 description 3
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 230000008855 peristalsis Effects 0.000 description 3
- 230000028527 righting reflex Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 2
- -1 compound diphenoxylate Chemical class 0.000 description 2
- 229960004192 diphenoxylate Drugs 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical class [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000036578 sleeping time Effects 0.000 description 1
- MHQHHBYRYFICDV-UHFFFAOYSA-M sodium;pyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].O=C1CC(=O)[N-]C(=O)N1 MHQHHBYRYFICDV-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1322—Inorganic compounds; Minerals, including organic salts thereof, oligo-elements; Amino-acids, peptides, protein-hydrolysates or derivatives; Nucleic acids or derivatives; Yeast extract or autolysate; Vitamins; Antibiotics; Bacteriocins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/515—Animalis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention belongs to the field of adult milk powder, and discloses laxative sleep-aiding milk powder containing lactobacillus paracasei N1115 and a preparation method thereof. The invention utilizes the synergistic interaction between the lactobacillus paracasei and the gamma-aminobutyric acid to achieve the effects of lubricating intestinal tracts and relieving constipation, has good sleep-aiding effect and is suitable for long-term drinking; the milk powder is used for supplementing nutrition, regulating intestinal health and improving sleep after being eaten.
Description
Technical Field
The invention belongs to the field of adult milk powder, and relates to laxative sleep-aiding milk powder, in particular to laxative sleep-aiding milk powder containing lactobacillus paracasei N1115 and a preparation method thereof.
Background
With the progress of industrialization and urbanization, traditional lifestyles are being challenged, and fast-paced, high-stress lifestyles cause people to continuously reduce sleep time. Some clinical statistics show that about 43 percent of patients suffering from insomnia are caused by 'stomach disharmony', the Chinese medicine has the sentence saying that 'stomach disharmony is followed by sleeping restlessness', the words mean that stomach is uncomfortable, sleeping is not good, and gastrointestinal problems and sleeping disorders often coexist, so that the research on adult milk powder for simultaneously relieving sleeping disorders and regulating intestinal health is certainly favored by consumers.
The existing sleep-aiding milk powder is often poor in effects of adjusting intestinal health and relieving constipation, and the existing milk powder with good effects of relaxing bowels and conditioning intestinal tracts is general in sleep-aiding effect. Therefore, by adjusting the components and the proportion of the formula of the milk powder and searching for the components with synergistic interaction, the milk powder has a good effect of relaxing bowels and helping sleep, and has important significance.
Disclosure of Invention
The invention aims to provide laxative sleep-aiding milk powder containing lactobacillus paracasei N1115, which achieves the purposes of relaxing bowels and aiding sleep by adding lactobacillus paracasei N1115 powder and gamma-aminobutyric acid which have a synergistic effect;
the invention also aims to provide a preparation method of the laxative sleep-aiding milk powder containing lactobacillus paracasei N1115;
in order to achieve the purpose, the invention adopts the technical scheme that:
a laxative sleep-aiding milk powder containing lactobacillus paracasei N1115 comprises the following raw materials of effective components in parts by weight:
75-95 parts of milk powder, 10-15 parts of polydextrose, 1-10 parts of lactobacillus paracasei N1115 bacterial powder, 0.001-0.006 part of gamma-aminobutyric acid, 2-7 parts of white granulated sugar, 0.2-0.8 part of composite essence, 0.2-0.8 part of animal bifidobacterium bacterial powder and 0.2-0.8 part of bifidobacterium lactis bacterial powder.
The milk powder is cow milk powder which has been sterilized conventionally.
As a limitation, the lactobacillus paracasei N1115 powder, the bifidobacterium animalis powder and the bifidobacterium lactis powder are all active freeze-dried powder.
As another limitation, the total number of colonies of the Lactobacillus paracasei N1115 powder is 0.1X 1010～1×1010CFU/g; the total number of bacterial colonies of animal Bifidobacterium powder is 0.1 × 1010～1×1010CFU/g; the total bacterial colony count of the Bifidobacterium lactis powder is 0.1 × 1010～1×1010CFU/g。
The Lactobacillus paracasei N1115(Lactobacillus paracasei N1115) used in the invention is preserved in 17.3.2011 in China general microbiological culture collection center (the national patent office assigned patent microbiological collection center) of China microbiological culture collection management Committee No. 3 of West Lu No. 1 Hospital, the south China area, Beijing, with the preservation number: CGMCC No.4691, which is disclosed in Chinese invention patent with the patent number of 201110357058.8 for the first time;
the lactobacillus paracasei N1115 strain has good acid resistance and cholate resistance, the acid resistance and cholate resistance of the strain are far higher than those of other commercial strains, the strain can be adhered to intestinal epithelial cells of a human body, and the strain is a domestic novel probiotic capable of activating immune cells to enhance the immune regulation effect of an organism.
As a further limitation, the feedstock is prepared by sieving.
As a further limitation, the number of the sieved screens is 110-130.
The invention also provides a preparation method of the laxative sleep-aiding milk powder containing lactobacillus paracasei N1115, which is to uniformly mix all the raw materials to obtain the laxative sleep-aiding milk powder containing lactobacillus paracasei N1115.
And uniformly mixing for 330-390 s in a premixer until the color is uniform.
Due to the adoption of the technical scheme, compared with the prior art, the invention has the technical progress that:
(1) the lactobacillus paracasei N1115 powder with reasonable proportion is added, the bacterium has good acid resistance and cholate resistance, has good intestinal colonization effect, is propagated with animal bifidobacterium and bifidobacterium lactis in the intestinal tract in a large quantity, inhibits intestinal pathogenic bacteria, changes the pH value of the intestinal tract, stimulates intestinal peristalsis and increases the humidity of fecal mass, thereby playing a role in accelerating the feces to be discharged out of the body, and has better effects of lubricating the intestinal tract, relaxing bowels and relieving constipation compared with the effect of singly using the lactobacillus paracasei N1115 powder;
(2) the lactobacillus paracasei N1115 and the gamma-aminobutyric acid in reasonable proportion are added at the same time, and are synergistic, so that the sedative, hypnotic and anticonvulsant effects of the gamma-aminobutyric acid are further enhanced, and the sleep promoting effect is better;
(3) compared with the commercially available product, the raw materials used in the invention have simpler formula, and based on the synergistic interaction of lactobacillus paracasei N1115 and gamma-aminobutyric acid, the relatively simple raw materials are adopted to achieve good effects of relaxing the bowels and helping sleep;
the bowel-relaxing sleep-aiding milk powder containing lactobacillus paracasei N1115 is simple in preparation method, wide in raw material source, low in price, suitable for industrial production and used for preparing the bowel-relaxing sleep-aiding milk powder containing lactobacillus paracasei N1115.
Drawings
The invention will be described in further detail with reference to the accompanying drawings and specific embodiments;
FIG. 1 is a graph showing the results of the small intestine propulsion experiments in control group, constipation model group, positive control group, experiment group 1 and experiment group 2 in example 11;
FIG. 2 is a graph showing the results of the first-pellet black stool time in the mouse defecation experiments of the control group, constipation model group, positive control group, experiment group 1 and experiment group 2 in example 11;
FIG. 3 is a graph showing the results of the moisture content of mouse feces in the control group, constipation model group, positive control group, experiment group 1 and experiment group 2 mouse feces experiments in example 11;
FIG. 4 is a graph showing the results of the sleep time experiments with sodium pentobarbital in CG group, EG1 group and EG2 group in example 12;
FIG. 5 is a graph showing the results of the sleep latency experiments for sodium barbiturate in CG group, EG1 group and EG2 group in example 12.
Detailed Description
The present invention is further illustrated by the following specific examples, which are to be construed as merely illustrative, and not limitative of the remainder of the disclosure.
Examples 1-10 preparation method of laxative sleep-aiding milk powder containing Lactobacillus paracasei N1115
The preparation method comprises the steps of preparing laxative sleep-aiding milk powder containing lactobacillus paracasei N1115 in embodiments 1-10 respectively, weighing all raw materials which are sieved in advance according to the dosage shown in the table 1, mixing the raw materials in a premixer for 330-390 seconds, and mixing the raw materials until the color is uniform to obtain the laxative sleep-aiding milk powder containing lactobacillus paracasei N1115 in embodiments 1-10 (correspondingly marked as M1-M10);
the specific raw materials and the dosage are shown in table 1, and the specific process parameters are shown in table 2:
TABLE 1 examples 1-10 Table of ingredients of laxative sleep-aiding milk powder containing Lactobacillus paracasei N1115
TABLE 2 technological parameters of examples 1-10A milk powder containing Lactobacillus paracasei N1115 for relaxing bowels and improving sleep
Wherein, the bifidobacterium animalis Bb12 bacterial powder and the bifidobacterium lactis HN019 bacterial powder are general active freeze-dried bacterial powder sold in the market;
although the present invention uses the above-mentioned strain, but is not limited thereto, those skilled in the art will appreciate that all strains of the same species having the same properties can achieve the technical effects of the present invention;
the obtained laxative sleep-aiding milk powder containing lactobacillus paracasei N1115 is used for achieving the purposes of supplementing nutrition, regulating intestinal health and improving sleep conditions after being eaten.
EXAMPLE 11 bowel health regulating action of laxative sleep-aiding milk powder containing Lactobacillus paracasei N1115
Firstly, preparing an intragastric lavage sample:
control milk powder N1: a control milk powder N1 was prepared according to the partial starting material and preparation method of example 1, which differs from the laxative sleep-aid milk powder M1 containing Lactobacillus paracasei N1115 only in that no gamma-aminobutyric acid was present in the starting material; preparing a gastric lavage sample corresponding to the control milk powder N1 by dissolving 30g of milk powder in 200 ml of 50 ℃ warm water;
laxative sleep-aiding milk powder M1 containing lactobacillus paracasei N1115: preparing the intragastric lavage sample in the same way;
II, experimental design and results:
selecting 50 Kunming male mice with the weight of 20 +/-2 g, randomly dividing the 50 Kunming male mice into 5 groups, wherein each group comprises 10 mice, namely a control group, a constipation model group, a positive control group, an experiment group 1 and an experiment group 2, each group adopts an isometric gavage method, the dosage is 20 mL/(kg.d), corresponding samples are gavaged, each group is continuously gavage for 10d, and water is freely drunk and standard feed is freely taken;
after 10 days of gastric lavage, constructing a constipation model, preparing ink, randomly selecting 5 ink in each group to perform small intestine propulsion experiments, and calculating the small intestine propulsion rate; recording defecation conditions of other groups of mice to obtain first black excrement discharge time and calculate excrement water content;
A1) the corresponding gavage samples for each group were as follows:
firstly, perfusing distilled water into a control group;
② the constipation model group is filled with stomach distilled water;
③ the positive control group is filled with distilled water;
experimental group 1 gavage control milk powder N1;
experiment group 2 drenched the laxative sleep-aiding milk powder M1 containing Lactobacillus paracasei N1115;
A2) constructing a constipation model:
after 10 days of gastric lavage, after all mice are fasted and fed without water for 24 hours, the constipation model is constructed by 0.025 percent of compound diphenoxylate in each group except the control group, the constipation model is constructed by adopting a one-time gastric lavage administration mode, and the dosage of the compound diphenoxylate is 20ml/kg of each mouse;
A3) preparation and use of an ink sample:
preparing an ink sample: mixing Arabic gum 5g with distilled water 40mL, boiling until the mixture is clear and transparent, mixing with activated carbon powder 2.5g, boiling for 3 times, cooling, and diluting with distilled water to 50mL to obtain an ink sample.
Ink samples were used: after 0.5h of constructing a constipation model, each group of gastric lavage ink samples according to the ratio of 20 mL/kg:
ink samples for control and constipation model groups: ink samples + distilled water, 50% each;
positive control ink samples: ink samples + phenolphthalein tablet solutions, 50% each; wherein the phenolphthalein tablet can be used for treating constipation, and the phenolphthalein tablet solution is prepared by dissolving 20mg phenolphthalein tablet in 1kg distilled water;
experimental group 1 ink samples: the ink sample and the reference milk powder N1 are mixed together in a mixing mode of 50 percent respectively;
experimental group 2 ink samples: the ink sample and the laxative sleep-aiding milk powder M1 containing lactobacillus paracasei N1115 are mixed in the same way, wherein the content of each milk powder is 50%;
A4) small intestine propulsion experiments and results:
after the corresponding Chinese ink samples are perfused into the stomach, 5 Chinese ink samples are randomly selected from each group for carrying out small intestine propulsion experiments, the mice are sacrificed after 20min of perfusion, dissection is carried out, the total length of the small intestine and the distance from the pylorus at the lower end of the stomach to the front edge of ink movement are measured, and the small intestine propulsion rate is calculated according to a formula I:
the experimental result is shown in fig. 1, and as can be seen from fig. 1, the small intestine propulsion rate of the constipation model group is obviously lower than that of the control group, which indicates that the constipation model is successfully constructed; the small intestine propulsion rate of the positive control group, the experimental group 1 and the experimental group 2 is between that of the control group and that of the constipation model group, the result of the experimental group 2 is closer to that of the control group, while the positive control group and the experimental group 1 are obviously inferior to that of the experimental group 2, which shows that the intestinal tract of the mice of the experimental group 2 is more lubricated and the peristalsis is better, therefore, the laxative sleep-aiding milk powder containing lactobacillus paracasei N1115 has an outstanding laxative effect.
A5) Mouse defecation experiments and results:
after the corresponding Chinese ink samples are perfused, feeding the remaining 25 mice in a single cage to ensure sufficient feed and water, observing the defecation condition of the mice in 6h, recording the first defecation time of each mouse, the number of 6h defecation grains and the total defecation mass, drying all the feces discharged in 6h of each mouse at the constant temperature of 65 ℃ until the feces are constant in mass, wherein the obtained data is the dry mass of the feces of the mice, and the moisture content of the feces of the mice is calculated according to a formula II:
the experimental results are shown in fig. 2 and 3, and it can be seen from fig. 2 that the black stool discharging time of the first mouse particle in the constipation model group is obviously longer than that of the control group, which indicates that the constipation model is successfully constructed; the small intestine propulsion rate of the positive control group, the experimental group 1 and the experimental group 2 is between that of the control group and that of the constipation model group, the result of the experimental group 2 is closer to that of the control group, while the positive control group and the experimental group 1 are obviously inferior to that of the experimental group 2, which shows that the intestinal tract of the mice of the experimental group 2 is more lubricated and the peristalsis is better, therefore, the laxative sleep-aiding milk powder containing lactobacillus paracasei N1115 has good laxative effect;
as can be seen from FIG. 3, the moisture content of the feces of the positive control group, the experimental group 1 and the experimental group 2 is between the moisture content of the feces of the control group and the constipation model group, the result of the experimental group 2 is closer to that of the control group, while the moisture content of the feces of the positive control group and the experimental group 1 is obviously inferior to that of the experimental group 2, which indicates that the intestinal tract of the mice of the experimental group 2 is more lubricated and the feces are slightly dried, so that the laxative sleep-aiding milk powder containing Lactobacillus paracasei N1115 can effectively prevent constipation;
in conclusion, the small intestine propulsion rate and the feces water content of the experimental group 2 are higher than those of the experimental group 1 and the positive control group, and the first-particle black stool discharging time is lower than those of the experimental group 1 and the positive control group, so that compared with the experimental group 1 and the positive control group, the experimental group 2 has better performance in regulating the intestinal tract and relaxing the bowel, namely the lactobacillus paracasei N1115 and the gamma-aminobutyric acid are synergized, so that the milk powder containing the lactobacillus paracasei N1115 for relaxing the bowels and improving the sleep has outstanding effects of lubricating the intestinal tract and relieving the constipation, and can regulate the intestinal tract health.
Example 12 sleep-aid action of laxative sleep-aid milk powder containing Lactobacillus paracasei N1115
Selecting 36 Kunming male mice with the weight of 20 +/-2 g, randomly dividing the 36 Kunming male mice into 3 groups, wherein each group comprises 12 mice, namely a control group-CG group, an experimental group-EG 1 group and an EG2 group, each group adopts an equal-volume intragastric perfusion method, the dosage is 20 mL/(kg. d), and each group is perfused with corresponding samples for 30 days by continuous intragastric perfusion, and during the period, the mice freely drink water and freely eat standard feeds;
after 30 days of gastric lavage, randomly selecting 6 mice from each group for carrying out pentobarbital sodium sleep time experiments, and recording the sleep time of the mice; carrying out barbiturate sodium sleep latency experiments on the other groups of mice, and recording the sleep latency;
B1) the corresponding gavage samples for each group were as follows:
(I) CG group intragastric distilled water;
(II) EG1 group gavage control milk powder N1, the preparation method is the same as example 11;
(III) EG2 group of laxative sleep-aiding milk powder M1 containing Lactobacillus paracasei N1115 for intragastric administration, and the preparation method is the same as the above;
B2) pentobarbital sodium sleeping time experiments and results:
after 20min after the corresponding sample of the last gastric lavage, randomly selecting 6 mice from each group to perform the pentobarbital sodium sleep time experiment, intraperitoneally injecting pentobarbital sodium into each group of mice according to the dosage of 50mg/kg bw, wherein the injection amount is 0.2mL/20g bw, taking the disappearance of righting reflex of the mice as a sleep judgment index, recording the condition that the pentobarbital sodium of each group affects the sleep time of the mice, and if the sleep time of the mice of the experimental group is prolonged compared with that of the control group, judging that the experimental result is positive.
The results are shown in figure 4, the EG1 group has no significant difference (P < 0.05) from the CG group, the EG2 group has significant difference (P < 0.05) from the CG group, the sleep time of the EG2 group is obviously prolonged compared with the CG group, namely, the test result of the sleep time of sodium pentobarbital is positive, which indicates that the lactobacillus paracasei N1115 and the gamma-aminobutyric acid are synergistic. Therefore, the bowel-relaxing sleep-aiding milk powder containing lactobacillus paracasei N1115 can obviously prolong the sleep time of mice;
B3) barbiturate sodium sleep latency period experiment and results:
after 20min of the last time of perfusing the corresponding sample, carrying out a barbiturate sleep latency period experiment on the other groups of mice which are not subjected to the pentobarbital sodium sleep time experiment, carrying out intraperitoneal injection of barbital sodium at a dose of 280mg/kg bw on the mice of each group, wherein the injection amount is 0.1mL/kg bw, the disappearance of the righting reflex of the mice is used as a sleep-entering judgment standard for more than 60s, and the time from the injection of the barbital sodium to the disappearance of the righting reflex of the mice is used as a sleep latency period, so that whether the sleep latency period of the barbital sodium injection mice can be shortened or not in the comparative experiment group is judged, and if yes, the experiment result is judged to be positive.
The experimental result is shown in fig. 5, the EG1 group has no significant difference (P is less than 0.05) from the CG group, the EG2 group has significant difference (P is less than 0.05) from the CG group, the sleep latency time of the EG2 group mice is obviously shortened compared with the CG group, namely the barbiturate sodium sleep latency experimental result is positive, which shows that the synergy of lactobacillus paracasei N1115 and gamma-aminobutyric acid is realized, therefore, the laxative sleep-aiding milk powder containing lactobacillus paracasei N1115 can obviously shorten the sleep latency time of the mice;
in conclusion, the EG2 group has positive results in the experiment for prolonging the sleep time of the pentobarbital sodium and the experiment for the sleep latency period of the barbital sodium, the tested object can be judged to have the effect of improving the sleep according to the technical specifications of health food inspection and evaluation, and the result shows that the laxative sleep-aiding milk powder containing the lactobacillus paracasei N1115 has the effect of improving the sleep.
It should be noted that the above-mentioned embodiments are only preferred embodiments of the present invention, and are not intended to limit the present invention in other forms, and any person skilled in the art may use the above-mentioned technical content as a teaching to make changes or modifications to the equivalent embodiments with equivalent changes, but all those simple changes, equivalent changes and modifications made to the above-mentioned embodiments without departing from the technical spirit of the present invention, and still all those embodiments are within the scope of the present invention as claimed in the claims.
Claims (6)
1. The laxative sleep-aiding milk powder containing lactobacillus paracasei N1115 is characterized in that raw materials for preparing effective components of the milk powder comprise the following components in parts by weight:
75-95 parts of milk powder, 10-15 parts of polydextrose, 1-10 parts of lactobacillus paracasei N1115 bacterial powder, 0.001-0.006 part of gamma-aminobutyric acid, 2-7 parts of white granulated sugar, 0.2-0.8 part of composite essence, 0.2-0.8 part of animal bifidobacterium bacterial powder and 0.2-0.8 part of bifidobacterium lactis bacterial powder.
2. The laxative sleep-aiding milk powder containing lactobacillus paracasei N1115 according to claim 1, wherein the lactobacillus paracasei N1115 powder, the bifidobacterium animalis powder and the bifidobacterium lactis powder are all live freeze-dried powder.
3. A powdered milk containing Lactobacillus paracasei N1115 for relaxing bowels and improving sleep according to claim 1 or 2, wherein the total number of bacterial colonies of Lactobacillus paracasei N1115 is 0.1 x 1010～1×1010CFU/g; the total number of bacterial colonies of animal Bifidobacterium powder is 0.1 × 1010～1×1010CFU/g; the total bacterial colony count of the Bifidobacterium lactis powder is 0.1 × 1010～1×1010 CFU/g。
4. The laxative sleep-aiding milk powder containing lactobacillus paracasei N1115 as claimed in claim 1 or 2, wherein the raw materials are all prepared by sieving.
5. The laxative sleep-aiding milk powder containing lactobacillus paracasei N1115 as claimed in claim 4, wherein the number of the sieved meshes is 110-130.
6. A preparation method of the laxative sleep-aiding milk powder containing lactobacillus paracasei N1115 as claimed in any one of claims 1 to 5, characterized in that all raw materials are uniformly mixed to obtain the laxative sleep-aiding milk powder containing lactobacillus paracasei N1115.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011562978.9A CN112602778A (en) | 2020-12-25 | 2020-12-25 | Laxative sleep-aiding milk powder containing lactobacillus paracasei N1115 and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011562978.9A CN112602778A (en) | 2020-12-25 | 2020-12-25 | Laxative sleep-aiding milk powder containing lactobacillus paracasei N1115 and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112602778A true CN112602778A (en) | 2021-04-06 |
Family
ID=75247843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011562978.9A Withdrawn CN112602778A (en) | 2020-12-25 | 2020-12-25 | Laxative sleep-aiding milk powder containing lactobacillus paracasei N1115 and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112602778A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110882280A (en) * | 2019-06-27 | 2020-03-17 | 内蒙古伊利实业集团股份有限公司 | New application of lactobacillus paracasei K56 |
| CN116549494A (en) * | 2023-07-07 | 2023-08-08 | 四川合泰新光生物科技有限公司 | Beta-1, 3/alpha-1, 3-glucan compound composition with bowel relaxing function and preparation method and application thereof |
-
2020
- 2020-12-25 CN CN202011562978.9A patent/CN112602778A/en not_active Withdrawn
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110882280A (en) * | 2019-06-27 | 2020-03-17 | 内蒙古伊利实业集团股份有限公司 | New application of lactobacillus paracasei K56 |
| CN110882280B (en) * | 2019-06-27 | 2023-03-24 | 内蒙古伊利实业集团股份有限公司 | Novel application of lactobacillus paracasei K56 |
| CN116549494A (en) * | 2023-07-07 | 2023-08-08 | 四川合泰新光生物科技有限公司 | Beta-1, 3/alpha-1, 3-glucan compound composition with bowel relaxing function and preparation method and application thereof |
| CN116549494B (en) * | 2023-07-07 | 2023-09-01 | 四川合泰新光生物科技有限公司 | Beta-1, 3/alpha-1, 3-glucan compound composition with bowel relaxing function and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109123295B (en) | Probiotic solid beverage and preparation method thereof | |
| CN109329419A (en) | A kind of functional probiotics solid beverage and preparation method thereof for being able to maintain that intestinal health and improving immunity | |
| US11197901B2 (en) | Active substance of Lactobacillus paracasei GKS6, a composition comprising thereof and its use for promoting longevity | |
| WO2021114658A1 (en) | Bifidobacterium animalis subsp. lactis i797, method for separation and purification thereof, and use thereof | |
| CN108477617A (en) | A kind of probiotic powder and preparation method thereof to relax bowel | |
| CN106619743A (en) | Probiotic solid drink with hypoglycaemic effect and preparation method of probiotic solid drink | |
| CN107594284A (en) | A kind of solid beverage containing prebiotics and probiotics and preparation method thereof | |
| CN103636946B (en) | Preparation method and application of Chinese herbal medicine immunological enhancer for finless eel | |
| CN103053904A (en) | Compound functional sugar with function of adjusting intestinal flora | |
| CN108740251A (en) | A kind of probiotic gel candy and preparation method thereof improving constipation | |
| CN112056399A (en) | Probiotic composition for enhancing immunity and application thereof | |
| CN102373162B (en) | Lactobacillus salivarius M6 and antibacterial composition containing same | |
| CN104642870A (en) | Prebiotics composition | |
| US20220143114A1 (en) | Active substance of lactobacillus plantarum gkm3, a composition comprising thereof and its use for promoting longevity | |
| CN110140773A (en) | A kind of probiotics solid beverage, preparation method and applications | |
| CN112602778A (en) | Laxative sleep-aiding milk powder containing lactobacillus paracasei N1115 and preparation method thereof | |
| CN110917174A (en) | Oral probiotic capsule for regulating balance of female vaginal flora and preparation method thereof | |
| CN110692885A (en) | Probiotic health-care beverage for relieving constipation | |
| CN110959867A (en) | Composite probiotic microcapsule powder for emulsification and preparation method and application thereof | |
| CN109331045A (en) | It is a kind of containing Bee Pollen, the probiotic composition of active carbon and preparation method thereof | |
| CN110200186B (en) | Probiotic solid beverage and preparation method thereof | |
| CN114259050A (en) | Beverage for improving intestinal function and preparation method thereof | |
| CN111466572A (en) | Probiotic powder with intestinal tract regulating function and preparation method thereof | |
| CN113575963A (en) | Oligosaccharide probiotic composition and preparation method thereof | |
| CN114452308A (en) | Probiotics protective agent, microecological preparation prepared from same and application of probiotics protective agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210406 |